Polyvalent shed antigens stimulate both humoral and cellular immune responses.
Clinical Trials
MAVIS (Melanoma Antigen Vaccine Immunotherapy Study) is a multicenter, double-blind, placebo-controlled adaptive Phase III trial to assess the safety and efficacy of seviprotimut-L.